These immunotherapies include monoclonal antibodies directed against myeloma surface antigens, such as daratumumab targeting CD38 (ref. 21) and elotuzumab targeting SLAMF7/CD319 (refs. 22,23), as well as BCMA-targeted chimeric antigen receptor (CAR) T cell therapy24. The gene discussed is SLAMF7; the disease is plasma cell myeloma.